Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Delayed Quote. Delayed  - 05/30 05:35:06 pm
64.79 EUR   +0.45%
05/02 UCB FIRST THREE :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : shareholder meeting today
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
05/24/2016 05/25/2016 05/26/2016 05/27/2016 05/30/2016 Date
62.79(c) 64.78(c) 64.52(c) 64.5(c) 64.79 Last
1 153 677 567 441 329 503 332 710 141 871 Volume
-7.55% +3.17% -0.40% -0.03% +0.45% Change
More quotes
Financials (€)
Sales 2016 4 042 M
EBIT 2016 724 M
Net income 2016 453 M
Debt 2016 1 026 M
Yield 2016 1,93%
Sales 2017 4 285 M
EBIT 2017 879 M
Net income 2017 552 M
Debt 2017 676 M
Yield 2017 2,02%
P/E ratio 2016 25,20
P/E ratio 2017 20,41
EV / Sales 2016 3,36x
EV / Sales 2017 3,09x
Capitalization 12 546 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra, and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
05/19 UCB : Patent Issued for Systems for Automatically Administering Medication (USPT..
05/02 UCB FIRST THREE MONTHS INTERIM REPOR :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : Patent Issued for Method for Producing Protein (USPTO 9315565)
04/28 UCB : shareholder meeting today
04/25 UCB FIRST THREE MONTHS INTERIM REPOR :
04/21 UCB : Patent Issued for Protein Purification (USPTO 9309280)
04/21 UCB : Patent Issued for Chiral Intermediate, Process for Producing the Same and ..
04/14 UCB : Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab Wit..
04/04 AMGEN : and UCB present positive data at ENDO 2016 comparing romosozumab with te..
More news
Sector news : Pharmaceuticals - NEC
08:06a BIOGEN : FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, A..
07:07a ROCHE : First PT/INR home self-testing device with Bluetooth technology enabling..
06:05a BIOGEN : AZN's Falcon Hits Goal, FDA Approves MS Drug, CANF Awaits Data In June
02:55aDJBAYER : Invites Environmental Groups to Discuss Monsanto
05/29 JOHNSON & JOHNSON : Telling the stories of a son fallen in combat, and also vete..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/28 LANNETT : Structural Benefits Of The Kremers Acquisition: 100+% Upside
03/21 Amgen's romosozumab successful in late-stage study in men with osteoporosis
02/26 UCB backs out of epratuzumab development deal with Immunomedics
02/25 FDA clears Intellipharmaceutics' generic Keppra XR
02/22 Amgen's bone-forming antibody successful in late-stage osteoporosis study
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions